Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial
The Lancet. Gastroenterology & hepatology2017Vol. 3(1), pp. 25–36
Citations Over TimeTop 10% of 2017 papers
Philip N. Newsome, Richard Fox, Andrew King, Darren Barton, Nwe-Ni Than, Joanna Moore, Christopher Corbett, Sarah Townsend, James A. Thomas, Kathy Guo, Diana Hull, Heather Beard, Jacqui Thompson, Anne Atkinson, Carol Bienek, Neil McGowan, Indra Neil Guha, John Campbell, Dan Hollyman, Deborah Stocken, Christina Yap, Stuart J. Forbes
Abstract
National Institute of Health Research, The Sir Jules Thorn Charitable Trust.
Related Papers
- → Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte–colony‐stimulating factor by single‐dose administration of AMD3100, a CXCR4 antagonist(2005)230 cited
- → Mobilization and collection of CD34+ cells for autologous transplantation of peripheral blood hematopoietic progenitor cells in children: analysis of two different granulocyte-colony stimulating factor doses(2015)10 cited
- → Return of granulocyte transfusions(2000)23 cited
- → The timing of granulocyte–colony‐stimulating factor administration after chemotherapy does not affect stem and progenitor cell apheresis yield: a retrospective study of 65 cases(1999)12 cited
- → Predictive value of the steady-state peripheral blood progenitor cell (PBPC) counts for the yield of PBPC collected by leukapheresis after mobilization by granulocyte colony-stimulating factor (G-CSF) alone or chemotherapy and G-CSF [letter; comment](1996)11 cited